A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm	Active, not recruiting	Phase 2	2026-01-15		NCT05716087

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Guangzhou Lupeng Pharmaceutical Company LTD.	12

43 results · Page 1 of 2

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Affiliated Hospital of Hebei University	Baoding	China	8
AnHui Provincial Cancer Hospital	Hefei	China	16
Beijing Boren Hospital	Beijing	China	3
Beijing Cancer Hospital	Beijing	China	208
Beijing Friendship Hospital	Beijing	China	9
Fujian Cancer Hospital	Fuzhou	China	55
Fujian Medical University Union Hospital	Fuzhou	China	38
Gansu Provincial Cancer Hospital	Lanzhou	China	4
Harbin First Hospital	Harbin	China	3
Henan Cancer Hospital	Zhengzhou	China	98
Henan Provincial People's Hospital	Zhengzhou	China	44
Hubei Cancer Hospital	Wuhan	China	23
Hunan Cancer Hospital	Changsha	China	87
Jiangsu Cancer Hospital	Nanjing	China	22
Jiangsu Province Hospital	Nanjing	China	37
Meizhou people'shospital	Meizhou	China	1
Nanfang Hospital, Southern Medical University	Guangzhou	China	15
Peking University Third Hospital	Beijing	China	4
Qilu Hospital of Shandong University	Jinan	China	68
Shandong Cancer Hospital	Jinan	China	31
Shengjing Hospital of China Medical University	Shenyang	China	32
Sichuan Cancer Hospital	Chengdu	China	21
Sun Yat-Sen Memorial Hospital	Guangzhou	China	10
Sun Yat-sen University Cancer Center	Guangzhou	China	315
The First Affiliated Hospital of Anhui Medical University	Hefei	China	44

Clinical trials